Published in BMC Neurol on March 31, 2011
Safety & Efficacy of Nuberol Forte® in Pain Management (NFORT-EFFECT) | NCT04765787
Italian guidelines for primary headaches: 2012 revised version. J Headache Pain (2012) 1.10
Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension-type headache: meta-analysis of four randomized, double-blind, placebo-controlled, crossover studies. J Headache Pain (2014) 0.80
Novel analgesic combination of tramadol, paracetamol, caffeine and taurine in the management of moderate to moderately severe acute low back pain. J Orthop (2013) 0.79
Evidence and consensus recommendations for the pharmacological management of pain in India. J Pain Res (2017) 0.75
The International Classification of Headache Disorders: 2nd edition. Cephalalgia (2004) 49.94
Epidemiology faces its limits. Science (1995) 12.39
An SCN9A channelopathy causes congenital inability to experience pain. Nature (2006) 7.01
What is synergy? Pharmacol Rev (1989) 6.08
Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today (2006) 4.24
Multicomponent therapeutics for networked systems. Nat Rev Drug Discov (2005) 3.99
Algorithm for neuropathic pain treatment: an evidence based proposal. Pain (2005) 3.92
Relationship between nonphenacetin combined analgesics and nephropathy: a review. Ad Hoc Committee of the International Study Group on Analgesics and Nephropathy. Kidney Int (2000) 3.86
Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A (2003) 3.86
Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 3.49
Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology (2007) 3.43
Neurobiological mechanisms of the placebo effect. J Neurosci (2005) 3.41
Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA (2007) 3.16
Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature (1998) 2.88
Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache (2005) 2.80
The analgesic effects of caffeine in headache. Pain (1991) 2.69
EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol (2010) 2.53
Patterns of medication use by chronic and episodic headache sufferers in the general population: results from the frequent headache epidemiology study. Cephalalgia (2010) 2.35
The expected effect of a combination of agents: the general solution. J Theor Biol (1985) 2.06
Analgesic effect of acetaminophen in humans: first evidence of a central serotonergic mechanism. Clin Pharmacol Ther (2006) 2.01
Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia (2008) 2.01
Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J (2007) 2.00
Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache (2008) 1.95
Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol (2000) 1.95
Mechanism of action of paracetamol. Am J Ther (2005) 1.93
Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem (2005) 1.88
Combination analgesic efficacy: individual patient data meta-analysis of single-dose oral tramadol plus acetaminophen in acute postoperative pain. J Pain Symptom Manage (2002) 1.77
Paracetamol: new vistas of an old drug. CNS Drug Rev (2007) 1.63
Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol (1998) 1.60
From nociception to pain perception: imaging the spinal and supraspinal pathways. J Anat (2005) 1.60
Chronic migraine and medication overuse headache: clarifying the current International Headache Society classification criteria. Cephalalgia (2009) 1.59
Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther (2000) 1.58
Obituary to analgesic nephropathy--an autopsy study. Nephrol Dial Transplant (2006) 1.55
Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H(2) synthases. Proc Natl Acad Sci U S A (2002) 1.54
Intravenous administration of caffeine sodium benzoate for postdural puncture headache. Reg Anesth Pain Med (1999) 1.48
Is noradrenaline a significant factor in the analgesic effect of antidepressants? Pain (2003) 1.45
Medication overuse headache. Expert Opin Drug Saf (2006) 1.42
Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia (2009) 1.41
The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A (2006) 1.39
Comments on results of Scher et al. pertaining to nonprescription caffeine-containing combination analgesics. Cephalalgia (2010) 1.38
Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. Cephalalgia (2008) 1.38
The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. Eur J Pharmacol (2006) 1.27
Effects of oral caffeine on postdural puncture headache. A double-blind, placebo-controlled trial. Anesth Analg (1990) 1.25
Caffeine as an analgesic adjuvant. JAMA (1984) 1.17
Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol Rev (1993) 1.16
Analgesic use and renal function in men. JAMA (2001) 1.13
The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur J Pharmacol (1996) 1.10
Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney Int (1998) 1.10
Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus. Neuropharmacology (2005) 1.10
Caffeine accelerates absorption and enhances the analgesic effect of acetaminophen. J Clin Pharmacol (2007) 1.07
Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther (1994) 1.06
Analgesic strategies beyond the inhibition of cyclooxygenases. Trends Pharmacol Sci (2006) 1.05
Structure and organization of drug-target networks: insights from genomic approaches for drug discovery. Mol Biosyst (2009) 1.05
Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia (1996) 1.05
Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache (2005) 1.03
New drugs for migraine. J Headache Pain (2009) 1.02
Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain. Pain (2006) 1.01
Should caffeine abuse, dependence, or withdrawal be added to DSM-IV and ICD-10? Am J Psychiatry (1992) 1.01
The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. Eur J Pharmacol (2007) 0.99
Caffeine as an analgesic adjuvant. A double-blind study comparing aspirin with caffeine to aspirin and placebo in patients with sore throat. Arch Intern Med (1991) 0.95
Medication overuse headache. Curr Opin Neurol (2004) 0.94
Effects of caffeine and paracetamol alone or in combination with acetylsalicylic acid on prostaglandin E(2) synthesis in rat microglial cells. Neuropharmacology (2000) 0.93
Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine3 receptors: in vivo and in vitro evidence. J Pharmacol Exp Ther (1996) 0.92
Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia (2006) 0.92
A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future. Expert Opin Pharmacother (2008) 0.92
Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr (2000) 0.91
Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol (2004) 0.91
Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol (2004) 0.90
From molecules to systems: the importance of looking both ways. Stud Hist Philos Biol Biomed Sci (2009) 0.90
PHENACETIN AND RENAL DAMAGE AT A SWEDISH FACTORY. Acta Med Scand (1963) 0.89
Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther (2004) 0.89
Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia (2006) 0.88
Triptans--why once? Headache (2006) 0.87
Beyond monotherapy: rational polytherapy in migraine. Headache (1998) 0.87
Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol (2001) 0.87
Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia (2002) 0.86
Dopamine involvement in the migraine attack. Funct Neurol (2000) 0.86
Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia (1999) 0.86
Neuropathic pain: molecular complexity underlies continuing unmet medical need. J Med Chem (2007) 0.86
Genesis of analgesic nephropathy in the United Kingdom. Kidney Int (1978) 0.85
Self-medication: from European regulatory directives to therapeutic strategy. Fundam Clin Pharmacol (2003) 0.85
Indomethacin, alone and combined with prochlorperazine and caffeine, but not sumatriptan, abolishes peripheral and central sensitization in in vivo models of migraine. J Pain (2004) 0.85
Presynaptic mechanism of action induced by 5-HT in nerve terminals: possible involvement of ryanodine and IP3 sensitive 2+ stores. Comp Biochem Physiol A Mol Integr Physiol (2005) 0.84
Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium. J Headache Pain (2008) 0.84
Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci Lett (2009) 0.83
D2 dopamine receptor involvement in spinal dopamine-produced antinociception. Life Sci (1992) 0.83
Ibuprofen plus caffeine in the treatment of tension-type headache. Clin Pharmacol Ther (2000) 0.83
Evidence for pain modulation by pre- and postsynaptic noradrenergic receptors in the medulla oblongata. Brain Res (1985) 0.83
A safety assessment of fixed combinations of acetaminophen and acetylsalicylic acid, coformulated with caffeine. Ren Fail (1998) 0.83
Caffeine induces central cholinergic analgesia. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.83
Acetaminophen recruits spinal p42/p44 MAPKs and GH/IGF-1 receptors to produce analgesia via the serotonergic system. Mol Pharmacol (2006) 0.82
Effect of caffeine on ibuprofen analgesia in postoperative oral surgery pain. Clin Pharmacol Ther (1991) 0.82
Do caffeine-containing analgesics promote dependence? A review and evaluation. Clin Pharmacol Ther (2000) 0.82
Hypoalgesic effect of caffeine in experimental ischemic muscle contraction pain. Headache (1998) 0.82
Caffeine for the prevention and treatment of postdural puncture headache: debunking the myth. Neurologist (2007) 0.82
Non-phenacetin analgesics and analgesic nephropathy: clinical assessment of high users from a case-control study. Nephrol Dial Transplant (2008) 0.82
Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol (2007) 0.81
Impairment of pain inhibition in chronic tension-type headache. Pain (2005) 1.41
Comments on results of Scher et al. pertaining to nonprescription caffeine-containing combination analgesics. Cephalalgia (2010) 1.38
Post-ischaemic treatment with the cyclooxygenase-2 inhibitor nimesulide reduces blood-brain barrier disruption and leukocyte infiltration following transient focal cerebral ischaemia in rats. J Neurochem (2006) 1.37
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther (2007) 1.29
Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry (2002) 1.28
Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des (2008) 1.23
Signal transduction pathways regulating cyclooxygenase-2 in lipopolysaccharide-activated primary rat microglia. Glia (2005) 1.22
Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation (2007) 1.17
Caffeic acid phenethyl ester inhibits T-cell activation by targeting both nuclear factor of activated T-cells and NF-kappaB transcription factors. J Pharmacol Exp Ther (2003) 1.14
Coumarins from Opopanax chironium. New dihydrofuranocoumarins and differential induction of apoptosis by imperatorin and heraclenin. J Nat Prod (2004) 1.06
Traditionally used Thai medicinal plants: in vitro anti-inflammatory, anticancer and antioxidant activities. J Ethnopharmacol (2010) 1.06
Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry (2006) 1.05
Inhibition of LPS-induced iNOS and NO synthesis in primary rat microglial cells. Neurochem Int (2003) 1.00
Regulation of prostaglandin E2 synthase expression in activated primary rat microglia: evidence for uncoupled regulation of mPGES-1 and COX-2. Glia (2008) 1.00
Regional distribution of the prostaglandin E2 receptor EP1 in the rat brain: accumulation in Purkinje cells of the cerebellum. J Mol Neurosci (2005) 0.99
Effects of the cyclooxygenase-2 inhibitor nimesulide on cerebral infarction and neurological deficits induced by permanent middle cerebral artery occlusion in the rat. J Neuroinflammation (2005) 0.99
Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res (2004) 0.98
Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab (2008) 0.96
Arzanol, an anti-inflammatory and anti-HIV-1 phloroglucinol alpha-Pyrone from Helichrysum italicum ssp. microphyllum. J Nat Prod (2007) 0.95
Serotonin via 5-HT7 receptors activates p38 mitogen-activated protein kinase and protein kinase C epsilon resulting in interleukin-6 synthesis in human U373 MG astrocytoma cells. J Neurochem (2005) 0.94
Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol (2007) 0.93
Role of prostaglandins in neuroinflammatory and neurodegenerative diseases. Mediators Inflamm (2012) 0.91
Calcium ionophoretic and apoptotic effects of ferutinin in the human Jurkat T-cell line. Biochem Pharmacol (2004) 0.91
Interleukin-1 beta-induced expression of the prostaglandin E-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. J Neurochem (2006) 0.90
Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia. J Neuroinflammation (2012) 0.90
Period prevalence of self-reported headache in the general population in Germany from 1995-2005 and 2009: results from annual nationwide population-based cross-sectional surveys. J Headache Pain (2013) 0.89
Immunosuppressive activity of endovanilloids: N-arachidonoyl-dopamine inhibits activation of the NF-kappa B, NFAT, and activator protein 1 signaling pathways. J Immunol (2004) 0.89
Punicalagin inhibits neuroinflammation in LPS-activated rat primary microglia. Mol Nutr Food Res (2014) 0.88
Mesuol, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway. Antiviral Res (2005) 0.87
Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor. Brain Res (2006) 0.86
Amyloid beta peptide (25-35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes. Neurochem Int (2006) 0.86
Denbinobin inhibits nuclear factor-kappaB and induces apoptosis via reactive oxygen species generation in human leukemic cells. Biochem Pharmacol (2009) 0.86
[Chronic diseases, psychological distress and coping -- challenges for psychosocial care in medicine]. Psychother Psychosom Med Psychol (2003) 0.86
Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia. J Neuroinflammation (2010) 0.85
The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem Pharmacol (2005) 0.85
Basiliolides, a class of tetracyclic C19 dilactones from Thapsia garganica, release Ca(2+) from the endoplasmic reticulum and regulate the activity of the transcription factors nuclear factor of activated T cells, nuclear factor-kappaB, and activator protein 1 in T lymphocytes. J Pharmacol Exp Ther (2006) 0.84
The growth inhibitory activity of the Cimicifuga racemosa extract Ze 450 is mediated through estrogen and progesterone receptors-independent pathways. Planta Med (2006) 0.84
No response of plasma substance P, but delayed increase of interleukin-1 receptor antagonist to acute psychosocial stress. Life Sci (2006) 0.84
Early life stress differentially modulates distinct forms of brain plasticity in young and adult mice. PLoS One (2012) 0.84
Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in activated rat microglial cells. Arch Biochem Biophys (2008) 0.83
Minocycline reduces prostaglandin E synthase expression and 8-isoprostane formation in LPS-activated primary rat microglia. Immunopharmacol Immunotoxicol (2011) 0.83
COX-1/COX-2 inhibitors based on the methanone moiety. Eur J Med Chem (2002) 0.82
Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties. Arzneimittelforschung (2002) 0.82
Effects of sleep deprivation on nocturnal cytokine concentrations in depressed patients and healthy control subjects. J Neuropsychiatry Clin Neurosci (2012) 0.81
A minocycline derivative reduces nerve injury-induced allodynia, LPS-induced prostaglandin E2 microglial production and signaling via toll-like receptors 2 and 4. Neurosci Lett (2013) 0.81
Long-term protective effect of atorvastatin in permanent focal cerebral ischemia. Brain Res (2005) 0.81
Clinical relevance of efficacy endpoints in OTC headache trials. Headache (2009) 0.81
Substance P and affective disorders: new treatment opportunities by neurokinin 1 receptor antagonists? Neuropsychobiology (2002) 0.81
The acetaminophen-derived bioactive N-acylphenolamine AM404 inhibits NFAT by targeting nuclear regulatory events. Biochem Pharmacol (2006) 0.80
Prostaglandin E2 synthesis in human monocyte-derived dendritic cells. Int J Mol Med (2003) 0.80
1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline-induced apoptosis in the human neuroblastoma cell line SK-N-SH. J Neurochem (2004) 0.80
Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production. J Neuroimmunol (2006) 0.80
The future of genetic testing for drug response. Dialogues Clin Neurosci (2004) 0.80
New treatment options using 5-HT3 receptor antagonists in rheumatic diseases. Curr Top Med Chem (2006) 0.79
Medication overuse headache--comments on the current International Headache Society classification criteria. Cephalalgia (2010) 0.79
Effects of substance P and its antagonist L-733060 on long term potentiation in guinea pig hippocampal slices. Prog Neuropsychopharmacol Biol Psychiatry (2005) 0.79
Inhibition of Neuroinflammation in LPS-Activated Microglia by Cryptolepine. Evid Based Complement Alternat Med (2013) 0.79
Endogenous N-acyl-dopamines induce COX-2 expression in brain endothelial cells by stabilizing mRNA through a p38 dependent pathway. Biochem Pharmacol (2010) 0.79
Modulation of catecholamine release from rat striatal slices by the fixed combination of aspirin, paracetamol and caffeine. Pharmacol Res (2006) 0.78
Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept. Arzneimittelforschung (2002) 0.78
Effects of substance P on memory and mood in healthy male subjects. Hum Psychopharmacol (2007) 0.78
Mechanisms of anti-inflammatory property of Anacardium occidentale stem bark: inhibition of NF-κB and MAPK signalling in the microglia. J Ethnopharmacol (2012) 0.78
5-HT3 receptor antagonist for the treatment of tendinopathy. Nat Clin Pract Rheumatol (2008) 0.78
OTC analgesics in headache treatment: open-label phase vs randomized double-blind phase of a large clinical trial. Headache (2009) 0.78
Identification of 5-HT3 receptors on human platelets: increased surface immunoreactivity after activation with adenosine diphosphate (ADP) and thrombin receptor-activating peptide (TRAP). Thromb Haemost (2008) 0.78
Controlled type II diabetes mellitus has no major influence on platelet micro-RNA expression. Results from micro-array profiling in a cohort of 60 patients. Thromb Haemost (2013) 0.78
Bridelia ferruginea Produces Antineuroinflammatory Activity through Inhibition of Nuclear Factor-kappa B and p38 MAPK Signalling. Evid Based Complement Alternat Med (2012) 0.78
Serotonin mediates PGE2 overexpression through 5-HT2A and 5-HT3 receptor subtypes in serum-free tissue culture of macrophage-like synovial cells. Rheumatol Int (2008) 0.77
Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor. J Neurochem (2003) 0.77
Peripheral 5-HT1B and 5-HT2A receptors mediate the nociceptive response induced by 5-hydroxytryptamine in mice. Pharmacol Biochem Behav (2011) 0.77
Opposite effects of anandamide and N-arachidonoyl dopamine in the regulation of prostaglandin E and 8-iso-PGF formation in primary glial cells. J Neurochem (2009) 0.77
Resveratrol inhibits prostaglandin formation in IL-1beta-stimulated SK-N-SH neuronal cells. J Neuroinflammation (2009) 0.77
Imperatorin inhibits T-cell proliferation by targeting the transcription factor NFAT. Planta Med (2004) 0.77
Denbinobin, a naturally occurring 1,4-phenanthrenequinone, inhibits HIV-1 replication through an NF-kappaB-dependent pathway. Biochem Pharmacol (2008) 0.77
Tropisetron suppresses collagen synthesis in skin fibroblasts via α7 nicotinic acetylcholine receptor and attenuates fibrosis in a scleroderma mouse model. Arthritis Rheum (2013) 0.76
The anti-inflammatory effects of the 5-HT₃ receptor antagonist tropisetron are mediated by the inhibition of p38 MAPK activation in primary human monocytes. Int Immunopharmacol (2012) 0.76
Anti-neuroinflammatory properties of synthetic cryptolepine in human neuroblastoma cells: possible involvement of NF-κB and p38 MAPK inhibition. Eur J Med Chem (2013) 0.76
Detrimental effects of tropisetron on permanent ischemic stroke in the rat. BMC Neurosci (2008) 0.76
No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. Eur Neuropsychopharmacol (2005) 0.76
1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) induces apoptosis in human neuroblastoma cell lines. Ann N Y Acad Sci (2003) 0.76
Synthesis and biological evaluation of 12-aminoacylphorboids. J Nat Prod (2010) 0.76
A review of evidence-based medicine and meta-analytic reviews in migraine. Cephalalgia (2007) 0.75
5-HT3 receptor antagonist for the treatment of tendinopathy. Nat Clin Pract Rheumatol (2008) 0.75
LDQ--validated for headache diseases? Cephalalgia (2010) 0.75
Anti-inflammatory effects of willow bark extract. Clin Pharmacol Ther (2003) 0.75
Comments on Allena et al.: "From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries". J Headache Pain (2009) 0.75
Evidence-based understanding of medication-overuse headache: clinical implications--a comment. Headache (2007) 0.75
Medication overuse headache in Scandinavia--comments and questions. Cephalalgia (2010) 0.75
Nonsteroidal drugs and Alzheimer's disease. N Engl J Med (2002) 0.75
Letter to the editor concerning Fritsche et al. Prevention of medication overuse in patients with migraine. Pain 2010;151:404-13. Pain (2011) 0.75
Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment. Psychiatry Res (2005) 0.75
Medication overuse headache. Expert Opin Drug Saf (2007) 0.75